Case details

Merger control

Case reference

CCENT/2010/6 - Cephalon/Mepha

Acquiring

Cephalon, Inc.

Description

a company incorporated under the laws of the State of Delaware (USA) which carries out its economic activity in the pharmaceutical industry; it develops, produces and markets medicines, especially key medicines in the therapeutic areas relating to the central nervous system, pain, inflammatory diseases and oncology.

Acquired

Mepha AG

Description

a Swiss company operating in the pharmaceutical industry; it holds a significant portfolio of generics and brand generics and is recognised for its research, particularly in the field of malaria.

Sector

Extractive and manufacturing Industries

Activity (NACE)

C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

Applicable legislation

Art. 9(1)(a) (Law 18)

Notification thresholds

Market share

Type of merger

Conglomerate

Cooperation with sector regulators

Status

Closed

Type of Investigation

Phase 1

AdC’s decision

Case description

Notified on 9 February 2010, this merger operation consists of the acquisition, by Cephalon, Inc. (Cephalon), of exclusive control of the company Mepha AG (Mepha) and its subsidiaries, including the Portuguese company Mepha Portugal Lda.

Timeline

2010-03-11

Competition Authority Council adopts a decision of non-opposition to Merger No. 6/2010/Cephalon/Mepha

2010-02-18

Publication of the announcement

Top links

Case details